当前位置：
X-MOL 学术
›
Blood Cancer J.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2020-03-02 , DOI: 10.1038/s41408-020-0297-2 Maria Gavriatopoulou 1 , Evangelos Terpos 1 , Ioannis Ntanasis-Stathopoulos 1 , Panagiotis Malandrakis 1 , Evangelos Eleutherakis-Papaiakovou 1 , Athanasios Papatheodorou 2 , Nikolaos Kanellias 1 , Magdalini Migkou 1 , Despina Fotiou 1 , Ioanna Dialoupi 1 , Maria Roussou 1 , Nikoletta-Aikaterini Kokkali 1 , Efstathios Kastritis 1 , Meletios A Dimopoulos 1
中文翻译：
在新诊断的多发性骨髓瘤患者中，ASCT后与卡非佐米，来那度胺和地塞米松（KRd）合并可导致较高的最小残留疾病阴性率，并改善骨代谢，而无需使用双膦酸盐。
更新日期：2020-03-02
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2020-03-02 , DOI: 10.1038/s41408-020-0297-2 Maria Gavriatopoulou 1 , Evangelos Terpos 1 , Ioannis Ntanasis-Stathopoulos 1 , Panagiotis Malandrakis 1 , Evangelos Eleutherakis-Papaiakovou 1 , Athanasios Papatheodorou 2 , Nikolaos Kanellias 1 , Magdalini Migkou 1 , Despina Fotiou 1 , Ioanna Dialoupi 1 , Maria Roussou 1 , Nikoletta-Aikaterini Kokkali 1 , Efstathios Kastritis 1 , Meletios A Dimopoulos 1
Affiliation
中文翻译：
在新诊断的多发性骨髓瘤患者中，ASCT后与卡非佐米，来那度胺和地塞米松（KRd）合并可导致较高的最小残留疾病阴性率，并改善骨代谢，而无需使用双膦酸盐。
京公网安备 11010802027423号